Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455

The cancer genome atlas pan-cancer analysis project

The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

The Somatic Genomic Landscape of Glioblastoma

Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,455

Immunogenic Cell Death in Cancer Therapy

Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

The prognostic landscape of genes and infiltrating immune cells across human cancers

Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,163

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056

Open source clustering software

de Hoon, M., Imoto, S., Nolan, J., & Miyano, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth078 · Cited by 3,047

Java Treeview—extensible visualization of microarray data

Saldanha, A. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth349 · Cited by 2,991

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

Coulie, P. G., den Eynde, B. J. V., van der Bruggen, P., & Boon, T. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3670 · Cited by 1,176

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869

PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress

Verfaillie, T., Rubio, N., Garg, A. D., Bultynck, G., Rizzuto, R., Decuypere, J.-P., Piette, J. G., Linehan, C., Gupta, S., Samali, A., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.74 · Cited by 865

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death

Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800

Clinical use of dendritic cells for cancer therapy

Anguille, S., Smits, E., Lion, E., Tendeloo, V. F. V., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 723

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöehrer, A., Dieckmann, K. U., Filipits, M., Brandstetter, A., Weller, M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 594

Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

Grossman, S. A., Ye, X., Lesser, G. J., Sloan, A. E., Carraway, H. E., Desideri, S., & Piantadosi, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0774 · Cited by 580

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T. B., Cho, H.-I., Antonia, S. J., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 476

Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity

Dudek, A. M., Martin, S., Garg, A. D., & Agostinis, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00438 · Cited by 420

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

Garg, A. D., Galluzzi, L., Apétoh, L., Baert, T., Birge, R. B., Pedro, J. M. B., Breckpot, K., Brough, D., Chaurio, R. A., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 420

Elevated cd3+ and cd8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level

Kmiecik, J., Poli, A., Brons, N. H. C., Waha, A., Eide, G. E., Enger, P. Ø., Zimmer, J., & Chekenya, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.013 · Cited by 389

PROGgeneV2: enhancements on the existing database

Goswami, C. P., & Nakshatri, H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-970 · Cited by 369

Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma

Han, S., Zhang, C., Li, Q., Dong, J., Liu, Y., Huang, Y., Jiang, T., & Wu, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.162 · Cited by 348

Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β

Lohr, J., Ratliff, T., Huppertz, A., Ge, Y., Dictus, C., Ahmadi, R., Grau, S. J., Hiraoka, N., Eckstein, V., Ecker, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2557 · Cited by 337

Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas

Heimberger, A. B., Abou-Ghazal, M. K., Reina-Ortiz, C., Yang, D. S., Sun, W., Qiao, W., Hiraoka, N., & Fuller, G. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0320 · Cited by 333

ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death

Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305

Targeting adaptive glioblastoma: an overview of proliferation and invasion

Xie, Q. R., Mittal, S., & Berens, M. E. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou147 · Cited by 270

Immunocompetent murine models for the study of glioblastoma immunotherapy

Oh, T., Fakurnejad, S., Sayegh, E. T., Clark, A., Ivan, M. E., Sun, M. Z., Safaee, M., Bloch, O. G., James, C. D., & Parsa, A. T. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-107 · Cited by 256

Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas

Doucette, T. A., Rao, G., Rao, A. U. K., Shen, L., Aldape, K., Wei, J., Dziurzynski, K., Gilbert, M. R., & Heimberger, A. B. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0028 · Cited by 249

Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin‐mediated photodynamic therapy

Buytaert, E., Callewaert, G., Hendrickx, N., Scorrano, L., Hartmann, D., Missiaen, L., Vandenheede, J. R., Heirman, I., Grooten, J., & Agostinis, P. (2006) · The FASEB Journal · doi:10.1096/fj.05-4305fje · Cited by 245

Danger signalling during cancer cell death: origins, plasticity and regulation

Garg, A. D., Martin, S., Gołąb, J., & Agostinis, P. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.48 · Cited by 232

Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis

Garg, A. D., Ruysscher, D. D., & Agostinis, P. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1069938 · Cited by 230

Prognostic significance and mechanism of Treg infiltration in human brain tumors

Jacobs, J. F. M., Idema, A. J. S., Bol, K. F., Grotenhuis, J. A., de Vries, I. J. M., Wesseling, P., & Adema, G. J. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.05.020 · Cited by 222

Newcastle disease virotherapy induces long‐term survival and tumor‐specific immune memory in orthotopic glioma through the induction of immunogenic cell death

Koks, C., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., Vleeschouwer, S. D., Agostinis, P., Graf, N. M., & Gool, S. V. (2014) · International Journal of Cancer · doi:10.1002/ijc.29202 · Cited by 216

Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma

Han, S., Liu, Y., Li, Q., Li, Z., Hou, H., & Wu, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1629-7 · Cited by 211

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma

Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1651-7 · Cited by 196

MyD88: A Critical Adaptor Protein in Innate Immunity Signal Transduction

Warner, N. E., & Núñez, G. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1203103 · Cited by 185

CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival

Yang, I., Tihan, T., Han, S. J., Wrensch, M., Wiencke, J. K., Sughrue, M. E., & Parsa, A. T. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.03.031 · Cited by 184

Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy

Fadul, C. E., Fisher, J. L., Hampton, T. H., Lallana, E. C., Li, Z., Gui, J., Szczepiorkowski, Z. M., Tosteson, T. D., Rhodes, C. H., Wishart, H. A., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318215e300 · Cited by 172

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma

Wong, E. T., Lok, E., Gautam, S., & Swanson, K. D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.238 · Cited by 155

CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas

Andaloussi, A. E., & Lesniak, M. S. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9314-y · Cited by 142

Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine

Chen, H., Wang, P.-H., Chen, S.-S., Wen, C.-C., Chen, Y., Yang, W., & Yang, N. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1258-9 · Cited by 138

Hypericin‐induced photosensitization of HeLa cells leads to apoptosis or necrosis

Vantieghem, A., Assefa, Z., Vandenabeele, P., Declercq, W., Courtois, S. J., Vandenheede, J. R., Merlevede, W. J., de Witte, P. A. M., & Agostinis, P. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01416-1 · Cited by 135

BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton

Maes, H., Eygen, S. V., Krysko, D. V., Vandenabeele, P., Nys, K., Rillaerts, K., Garg, A. D., Verfaillie, T., & Agostinis, P. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.94 · Cited by 130

Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy

Sengupta, S., Marrinan, J. E., Frishman, C., & Sampath, P. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/831090 · Cited by 129

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

Heimberger, A. B., Sun, W., Hussain, S. F., Dey, M., Crutcher, L. M., Aldape, K., Gilbert, M. R., Hassenbusch, S. J., Sawaya, R. A., Schmittling, B., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-046 · Cited by 126

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

Ciampricotti, M., Hau, C., Doornebal, C. W., Jonkers, J., & de Visser, K. E. (2012) · Nature Medicine · doi:10.1038/nm.2652 · Cited by 108

Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients

Fong, B., Jin, R. M., Wang, X., Safaee, M., Lisiero, D. N., Yang, I., Li, G., Liau, L. M., & Prins, R. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032614 · Cited by 108

DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma

Maes, W., Galicia, G., Verbinnen, B., Boon, L., Vleeschouwer, S. D., Ceuppens, J. L., & Gool, S. V. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-004 · Cited by 107

Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components

Lin, T.-J., Lin, H.-T., Chang, W.-T., Pradeep Mitapalli., S., Hsiao, P., Yin, S., & Yang, N. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0435-9 · Cited by 103

Predicting the “usefulness” of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European survey

For the European ALA Pediatric Brain Tumor Study Group, Stummer, W., Rodrigues, F., Schucht, P., Preuß, M., Wiewrodt, D., Nestler, U., Stein, M., Artero, J. M. C., Platania, N., et al. (2014) · Acta Neurochirurgica · doi:10.1007/s00701-014-2234-2 · Cited by 103

Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface–Associated Calreticulin

Dudek-Perić, A. M., Ferreira, G. B., Muchowicz, A., Wouters, J., Prada, N., Martin, S., Kiviluoto, S., Winiarska, M., Boon, L., Mathieu, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2089 · Cited by 102

Impact of Tumour Volume on the Potential Efficacy of Therapeutic Vaccines

Gulley, J. L., Madan, R. A., & Schlom, J. (2011) · Current Oncology · doi:10.3747/co.v18i3.783 · Cited by 100

Dendritic Cell Therapy of High‐Grade Gliomas

Gool, S. V., Maes, W., Ardon, H., Verschuere, T., Cauter, S. V., & Vleeschouwer, S. D. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00316.x · Cited by 94

A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis

Rook, A. H., Wood, G. S., Duvic, M. A., Vonderheid, E. C., Tobia, A. J., & Cabana, B. E. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.02.039 · Cited by 91

Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin.

Alecu, M., Ursaciuc, C., Fl, H., Coman, G., Merlevede, W. J., Waelkens, E., & de Witte, P. A. M. (1998) · PubMed · Cited by 88

Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal

Garg, A. D., Elsen, S., Krysko, D. V., Vandenabeele, P., de Witte, P., & Agostinis, P. (2015) · Oncotarget · doi:10.18632/oncotarget.4754 · Cited by 87

Glioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity

Verschuere, T., Toelen, J., Maes, W., Poirier, F., Boon, L., Tousseyn, T., Mathivet, T., Gerhardt, H., Mathieu, V., Robert Kiss, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28426 · Cited by 85

NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy

Coupienne, I., Bontems, S., Dewaele, M., Rubio, N., Habraken, Y., Fulda, S., Agostinis, P., & Piette, J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.015 · Cited by 83

Photodynamic Therapy of Nonmelanoma Skin Cancer with Topical Hypericum perforatum Extract—A Pilot Study

Kacerovská, D., Pizinger, K., Majer, F., & Šmíd, F. (2008) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2007.00260.x · Cited by 79

The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma

Yue, Q., Zhang, X., Ye, H.-X., Wang, Y., Du, Z., Yao, Y., & Mao, Y. Q. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1314-0 · Cited by 72

Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model

Kim, T., Kim, C.-H., Park, J., Park, S.-D., Kim, C. K., Chung, D., & Hong, Y.-K. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00292-09 · Cited by 72

Tumour-infiltrating T-cell subpopulations in glioblastomas

Kim, Y., Jung, T., Jung, S., Jang, W., Moon, K., Kim, I., Lee, M. C., & Lee, J. (2011) · British Journal of Neurosurgery · doi:10.3109/02688697.2011.584986 · Cited by 70

Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models

Clarke, R. C. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005938428456 · Cited by 68

Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme

Hunn, M. K., Bauer, E., Wood, C. E., Gasser, O., Dzhelali, M., Ancelet, L. R., Mester, B., SHARPLES, K. J., Findlay, M. P. N., Hamilton, D. A., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1635-7 · Cited by 64

Dendritic Cell–Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma

Dey, M., Chang, A. L., Miska, J. M., Wainwright, D. A., Ahmed, A. U., Balyasnikova, I. V., Pytel, P., Han, Y., Tobias, A. L., Zhang, L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401607 · Cited by 63

Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma

Vandenberk, L., Garg, A. D., Verschuere, T., Koks, C., Belmans, J., Beullens, M., Agostinis, P., Vleeschouwer, S. D., & Gool, S. V. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1083669 · Cited by 60

Enhanced antitumour immunity by combined use of temozolomide and TAT‐survivin pulsed dendritic cells in a murine glioma

Kim, C., Woo, S., Park, J., Kim, H., Park, M., Park, S., Hong, Y., & Kim, T. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02680.x · Cited by 55

Regulatory T cells are not a strong predictor of survival for patients with glioblastoma

Thomas, A. A., Fisher, J. L., Rahme, G. J., Hampton, T. H., Baron, U., Olek, S., Schwachula, T., Rhodes, C. H., Gui, J., Tafe, L. J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou363 · Cited by 52

Hypericin for visualization of high grade gliomas: First clinical experience

Ritz, R., Daniels, R., Noell, S., Feigl, G. C., Schmidt, V., Bornemann, A., Ramina, K. F., Mayer, D., Dietz, K., Strauß, W. S. L., et al. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.12.021 · Cited by 45

Clinical Efficacy of Tumor Antigen-Pulsed DC Treatment for High-Grade Glioma Patients: Evidence from a Meta-Analysis

Cao, J., Zhang, X.-Y., Liu, J.-L., Li, D., Li, J., Liu, Y.-S., Wang, M., Xu, B., Wang, H., & Wang, Z.-X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107173 · Cited by 44

Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies

Stoll, G., Bindea, G., Mlecnik, B., Galon, J., Zitvogel, L., & Kroemer, G. (2015) · Oncotarget · doi:10.18632/oncotarget.4180 · Cited by 41

Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma

Cui, X., Xu, Z., Zhao, Z., Sui, D., Ren, X., Huang, Q., Qin, J., Hao, L., Wang, Z., Shen, L., et al. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.4891 · Cited by 37

Epigenetic biomarkers of T-cells in human glioma

Wiencke, J. K., Accomando, W. P., Zheng, S., Patoka, J., Dou, X., Phillips, J. J., Hsuang, G., Christensen, B. C., Houseman, E. A., Koestler, D. C., et al. (2012) · Epigenetics · doi:10.4161/epi.22675 · Cited by 36

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells

Eyrich, M. K., Schreiber, S. C., Rachor, J., Krauß, J., Pauwels, F., Hain, J., Wölfl, M., Lutz, M. B., Vleeschouwer, S. D., Schlegel, P. G., et al. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.02.017 · Cited by 34

Foxp3+ regulatory T cells are activated in spite of B7‐CD28 and CD40‐CD40L blockade

Vogel, I., Verbinnen, B., Maes, W., Boon, L., Gool, S. W. V., & Ceuppens, J. L. (2013) · European Journal of Immunology · doi:10.1002/eji.201242737 · Cited by 31

Active dendritic cell immunotherapy for glioblastoma: Current status and challenges

Polyzoidis, S., Tuazon, J., Brazil, L., Beaney, R. P., Al‐Sarraj, S., Doey, L. J., Logan, J., Hurwitz, V., Jarosz, J., Bhangoo, R. S., et al. (2014) · British Journal of Neurosurgery · doi:10.3109/02688697.2014.994473 · Cited by 24

Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS Consortium study.

Grossman, S. A., Ye, X., Lesser, G. J., Sloan, A. E., Carson, C., & Piantadosi, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2013 · Cited by 9

Prognostic value of the preoperative immunological profile in patients with glioblastoma

Gousias, K., Voulgaris, S., Vartholomatos, G., Voulgari, P. V., Kyritsis, A. P., & Markou, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.134104 · Cited by 8

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

Dendritic cells in cancer immunology and immunotherapy

Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,688

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027

The Microenvironmental Landscape of Brain Tumors

Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,924

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349

Next-generation immunogenic dendritic cell vaccines achieve a danger signaling and T cell-driven eradication of high-grade glioma

Garg, A., Vandenberk, L., Koks, C., Verschuere, T., Gool, S. V., & Agostinis, P. (2016) · Klinische Pädiatrie · doi:10.1055/s-0036-1593558

Irradiation of necrotic tumor cells used to pulse dendritic cells (DCs) potentiates DC vaccine-induced anti-tumor immunity in a mouse model of high-grade glioma

Vandenberk, L., Garg, A. D., Agostinis, P., Verschuere, T., Koks, C., Vleeschouwer, S. D., & Gool, S. V. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-s3-p163 · Cited by 1

Targeting immunogenic cell death for glioma immunotherapy

Mishchenko, T. A., Turubanova, V. D., Gorshkova, E. N., Krysko, O., Vedunova, M. V., & Krysko, D. V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.10.005 · Cited by 15

Immunogene op oxidatietherapie-gebaseerde tweede generatie dendritische celvaccins voor de behandeling van hooggradige gliomen

Vandenberk, L. (2016) · Lirias

Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas

Chistiakov, D. A., Chekhonin, I. V., Gurina, O. I., Bobryshev, Y. V., & Chekhonin, V. P. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160719110618 · Cited by 7